Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chin B Eap

Showing results (41-50 of 179) with videos related to

Pageof 18
Sort By:
The International Journal of Neuropsychopharmacology|March 24, 2005
Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopramGeorg Nikisch, Hans Agren, Chin B Eap, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 18, 2009
Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MSEva Choong, Serge Rudaz, Astrid Kottelat, et al.
Pharmacogenetics and Genomics|October 6, 2009
The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping testBeatrice Oneda, Severine Crettol, Evelyne Jaquenoud Sirot, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 15, 2002
Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot studyLina Steinacher, Pierre Vandel, Daniele F Zullino, et al.
Drug and Alcohol Dependence|March 1, 2003
Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone dosesMarc Shinderman, Sarz Maxwell, Marlyse Brawand-Amey, et al.
Journal of Psychopharmacology (Oxford, England)|December 8, 2004
Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspectsElio Ciusani, Daniele F Zullino, Chin B Eap, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 31, 2007
Time course of response to paroxetine: influence of plasma levelMarianne Gex-Fabry, Nicola Gervasoni, Chin B Eap, et al.
Experimental and Clinical Psychopharmacology|October 20, 2017
Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapyAnaïs Glatard, Maria Dobrinas, Mehdi Gholamrezaee, et al.
Chirality|April 23, 2002
Disposition of venlafaxine enantiomers in rats with hepatic encephalopathy after chronic drug treatmentCecilia Wikell, Chin B Eap, Martin Josefsson, et al.
Therapeutic Drug Monitoring|November 4, 2008
CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipientsSéverine Crettol, Jean-Pierre Venetz, Massimiliano Fontana, et al.
Pageof 18

Showing results (41-50 of 179) with videos related to

Sort By:
Pageof 18
The International Journal of Neuropsychopharmacology|March 24, 2005
Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopramGeorg Nikisch, Hans Agren, Chin B Eap, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 18, 2009
Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MSEva Choong, Serge Rudaz, Astrid Kottelat, et al.
Pharmacogenetics and Genomics|October 6, 2009
The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping testBeatrice Oneda, Severine Crettol, Evelyne Jaquenoud Sirot, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 15, 2002
Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot studyLina Steinacher, Pierre Vandel, Daniele F Zullino, et al.
Drug and Alcohol Dependence|March 1, 2003
Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone dosesMarc Shinderman, Sarz Maxwell, Marlyse Brawand-Amey, et al.
Journal of Psychopharmacology (Oxford, England)|December 8, 2004
Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspectsElio Ciusani, Daniele F Zullino, Chin B Eap, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 31, 2007
Time course of response to paroxetine: influence of plasma levelMarianne Gex-Fabry, Nicola Gervasoni, Chin B Eap, et al.
Experimental and Clinical Psychopharmacology|October 20, 2017
Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapyAnaïs Glatard, Maria Dobrinas, Mehdi Gholamrezaee, et al.
Chirality|April 23, 2002
Disposition of venlafaxine enantiomers in rats with hepatic encephalopathy after chronic drug treatmentCecilia Wikell, Chin B Eap, Martin Josefsson, et al.
Therapeutic Drug Monitoring|November 4, 2008
CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipientsSéverine Crettol, Jean-Pierre Venetz, Massimiliano Fontana, et al.
Pageof 18